スポンサーリンク
Department of Hematology, Dokkyo University School of Medicine | 論文
- Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia : results of the JALSG AML97 study
- Enhanced expression of the EVI1 gene in NUP98/HOXA-expressing leukemia cells
- Role of the RUNX1-EVI1 fusion gene in leukemogenesis
- RUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT-enhancer binding protein α function
- Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia : final results of Japanese multicenter cooperative study
- Morphological Diagnoses of the Japan Adult Leukemia Study Group Acute Myeloid Leukemia Protocols: Central Review
- A Prospective Study of Cyclosporine A Treatment of Patients with Low-Risk Myelodysplastic Syndrome : Presence of CD55^-CD59^- Blood Cells Predicts Platelet Response
- Low-Dose Cytarabine and Aclarubicin in Combination With Granulocyte Colony-Stimulating Factor (CAG Regimen) for Previously Treated Patients With Relapsed or Primary Resistant Acute Myelogenous Leukemia (AML) and Previously Untreated Elderly Patients With
- Leukemia-related transcription factor TEL/ETV6 expands erythroid precursors and stimulates hemoglobin synthesis
- Direct evidence of altered bone metabolixm caused by all-trans retinoic acid
- Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera
- Low-Level Expression of ETV6/TEL in Patients with Myelodysplastic Syndrome
- TEL/ETV6 Binds to Corepressor KAP1 via the HLH Domain
- Runx1/AML1 in Normal and Abnormal Hematopoiesis
- Low Frequency of BCL10 Gene Mutations in B-Cell Non-Hodgkin's Lymphoma
- Preferential inhibitory effect of soluble factor(s) in human bone marrow stromal cells on proliferation of K562 leukemia cells versus normal myeloid progenitor cells
- Presentation of familial Mediterranean fever in a heterozygous MEFV mutation triggered by immunosuppressive therapy for myelodysplastic syndrome
- Chromosomal abnormalities and oncogenes